Furthermore, intra-tumoral administration of ad.mda-7 in a phase I clinical trial showed evidence of clinical tumor suppressor effects [10], [11] and in support of the tumor suppressor effect of IL-24, there appears to be an inverse correlation between IL-24 expression levels and melanoma progression [5], [12]. The gene discussed is IL24; the disease is melanoma.